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ROStabolic reprogramming experienced by cancer cells as a result of the onset of
cellular proliferation has been added to the list of hallmarks of the cancer cell phenotype. Proliferation is
bound to the synchronous ﬂuctuation of cycles of an increased glycolysis concurrent with a restrained
oxidative phosphorylation. Mitochondria are key players in the metabolic cycling experienced during
proliferation because of their essential roles in the transduction of biological energy and in deﬁning the life–
death fate of the cell. These two activities are molecularly and functionally integrated and are both targets of
commonly altered cancer genes. Moreover, energetic metabolism of the cancer cell also affords a target to
develop new therapies because the activity of mitochondria has an unquestionable tumor suppressor
function. In this review, we summarize most of these ﬁndings paying special attention to the opportunity
that translation of energetic metabolism into the clinics could afford for the management of cancer patients.
More speciﬁcally, we emphasize the role that mitochondrial β-F1-ATPase has as a marker for the prognosis of
different cancer patients as well as in predicting the tumor response to therapy.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Cancer is considered a highly heterogeneous and complex genetic
disease that drives the progressive transformation of normal cells into
malignancy by a multistep and sequential ordered process. However,
and in addition to the contribution of genetic mutations in the well
established cancer genes (oncogenes and tumor suppressors), the
onset and progression of cancer is also bound to the cancer cell's
microenvironment and to other epigenetic events that contribute to
funnel the cell into malignancy. In this regard, large projects aimed at
deciphering the genetic changes occurring in tumors are being
questioned due to their limited applicability for the development of
effective therapies [1]. These arguments [1,2] suggest that the
development of an effective therapy against cancer will require the
targeting of the biological pathways commonly altered in the cancer
cell [1–5]. A starting point for this change of gear was the admirable
summary of the phenotype of the cancer cell in the following six
traits: an unlimited replicative potential, sustained angiogenesis,
evasion of apoptosis, self-sufﬁciency in growth signals, insensitivity to
anti-growth signals and tissue invasion and metastasis [2]. Quite
recently, the so-called “metabolic reprogramming” of the cancer cell
has been added as a seventh hallmark of the cancer phenotype [3,5].
Indeed, the incidence of malignant disorders increases with age
while the activity of mitochondrial oxidative metabolism diminishes in34 911 964 420.
).
ll rights reserved.most tissues during the ageing process. The apparent inverse correlation
that exists between mitochondrial activity and cellular transformation
was ﬁrst suggested by Otto Warburg back in the early days of the
previous century (for review see [6]). Hemade the seminal observation
that tumors have an abnormal high aerobic glycolysis and therefore
proposed that the bioenergetic activity ofmitochondriawas impaired in
the cancer cell [7,8]. However, with the advancement of molecular
biology, Warburg's hypothesis was largely neglected [9–11] or con-
sidered an epiphenomenon of cell transformation [12] until the early
days of the present century when it has been formally contrasted for a
relevant part of it [13,14] (for review see [5]). Indeed,many biochemical,
molecular, functional and clinical studies have conﬁrmed that most
human tumors and cancer cells display, even in the presence of oxygen,
increased rates of glucose consumption and of lactate release when
compared to normal tissues, extending the original Warburg observa-
tion to many different neoplasias [5]. However, the strongest backing to
the so-called Warburg phenotype of the tumors came from the
development and clinical application of tumor imaging by positron
emission tomography (PET) using 2-deoxy-2-[18F]ﬂuoro-D-glucose
(FDG) as a probe [15]. This technique, that actually measures the
glucose analogue captured by the tumor relative to its surrounding non-
tumor tissue, has proven to be one of the most effective techniques to
detect tumors and itsmetastasis aswell as for the staging, follow-up and
prognosis of cancer patients [14,15]. In this regard, both FDG-PET and
expression data of markers of mitochondrial bioenergetic function in
tumors of lung cancer patients, as well as ﬁndings on the rates of
glycolysis of cancer cells, have strongly supported that an altered
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abnormal aerobic glycolysis of the cancer cell [14].
The revitalization of energetic metabolism and hence, of the
“mitochondrial interest” in cancer biology, has boosted in recent years
because of the potential clinical and biotechnological interest that the
peculiarmetabolismof the cancer cell could afford in the combat of the
disease. A signiﬁcant number of studies devoted to understand the
molecular basis of the enforced glycolytic phenotype of cancers have
been developed.Most of themhave reported links between oncogenes
and/or tumor suppressors with the expression of enzymes of the
glycolytic pathwayand/or ofmitochondrial oxidativemetabolism (see
Section 4 Cancer genes and energetic metabolism). However, before
summarizing these ﬁndings, aimed at unveiling the precise mechan-
isms thatmight underlie a particular transformation event, the simpler
following scenario should be discussed: “an enforced glycolysis is a
prerequisite for malignant transformation because it is the pathway
that provides the metabolic precursors that could support cellular
proliferation”. In this review, we therefore summarize our present
understanding of the metabolic trait of the cancer cell stressing the
tumor suppressor function of mitochondrial oxidative phosphoryla-
tion.We further emphasize those aspects of energeticmetabolism that
might be exploited in the beneﬁt of patients to facilitate the rapid
translation of mitochondrial knowledge into the clinical setting. More
detailed accounts of the alterations of energetic metabolism found in
tumors have been recently summarized elsewhere [3,5].
2. The onset of cellular proliferation per se imposes a burst
in aerobic glycolysis
In non-proliferating cells the demand for glucose is low because
the complete oxidation of glucose bymitochondrial activity coupled to
respiration and oxidative phosphorylation provides a high yield of ATPFig. 1. The glycolytic phenotype of proliferation. (A) Schemes highlighting the metabolic phe
up by the cell is completely oxidized within mitochondria generating CO2 and a high yield of
species (ROS) in the respiratory chain. In contrast, proliferating cells take up much larger am
generate lactate that is further excreted from the cell. The high glycolytic ﬂux generates mo
precursors for the biosynthesis of the macromolecules required for proliferation. Mitochond
little CO2 and ROS and export to the cytoplasm the precursors required for lipid biosynthes
Upper panel represents the time course of the glycolytic ﬂux (blue) and synthesis of DNA (r
from reference [21]. The lower panel illustrates the origin of ATP generated in quiescent (Q
taken and redrawn from reference [23]. (C) Glycolytic ﬂux measured in different breast can
shown are means±s.e.m. of 3 independent experiments. ⁎, pb0.05 when compared to con(Fig. 1A). However, the efﬁcient mitochondrial extraction of biological
energy has the drawback that the glucose carbon skeleton is entirely
oxidized to CO2 and thus, provides no availablematter for biosynthetic
purposes (Fig. 1A). On the contrary, proliferating cells take up
considerably much larger amounts of glucose than non-proliferating
cells and partially oxidize the glucose carbon skeleton to lactate,
which is excreted from the cell in order to regenerate the NAD+ that is
required for glycolysis to proceed (Fig. 1A). An increased glycolysis
and truncatedmitochondrial activity affords the proliferating cell with
the large amounts of the precursors needed for the duplication of the
cellular material as well as of the energy for the assembly of precur-
sors into macromolecules (Fig. 1A). Indeed, highly proliferating cells
have a truncated Krebs cycle linked to an enhanced citrate release
from mitochondria for the purpose of supplying the cytoplasmic
acetyl-CoA that is required for the biosynthesis of fatty acids [16,17]
and cholesterol [18]. However, it should be noted that in cancer cells
the mitochondrial oxidation of glutamine could replenish with carbon
skeletons the Krebs cycle [19,20]. Besides, in the majority of cells
mitochondrial respiration is also responsible for the production of
reactive oxygen species (ROS) (Fig. 1A) that could become toxic
molecules and eventually damage DNA if the ROS scavenging
antioxidant defense is overwhelmed. A diminished mitochondrial
activity in the proliferating cell (Fig. 1A) warranties less production of
ROS at a time when DNA is most vulnerable because of its loosened
and naked state. The largely divergent diagrams depicted on Fig. 1A
illustrate two metabolic extreme situations for differentiated and
proliferating cells and Fig.1B and C provide some illustrative examples
of these traits in non-tumor and breast cancer cells, respectively.
Aerobic glycolysis is sharply increased in lymphocytes [21,22] and
thymocytes [23] when the cells are stimulated to proliferate (Fig. 1B).
In lymphocytes, the burst of glycolysis coincides with the peak of
synthesis of cellular DNA (Fig. 1B, upper panel) [21]. Concurrent withnotype of quiescent and proliferating cells. In quiescent cells, most of the glucose taken
ATP by oxidative phosphorylation. Mitochondrial activity also generates reactive oxygen
ounts of glucose that is partially oxidized in the cytoplasm by the glycolytic pathway to
st of cellular ATP requirements and provides the metabolic intermediates that become
ria in proliferating cells are not committed to energy generation and therefore produce
is. (B) Proliferation in normal cells is bound to the sharp increase in aerobic glycolysis.
ed) in lymphocytes stimulated to proliferate. These data have been taken and redrawn
, red bars) and proliferating (P, blue bars) thymocytes. The represented data have been
cer cells during proliferation (blue bars) and at conﬂuent stage (red bars). The results
ﬂuent by Student's t test.
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of ROS are arrested in proliferating thymocytes [23]. Likewise, when
breast cancer cells reach conﬂuence cellular proliferation is dimi-
nished and the glycolytic ﬂux is signiﬁcantly reduced (Fig. 1C).
Consistently, in the absence of growth factors that can stimulate
cellular proliferation the expression of glucose and amino acid
transporters are lost in human T-cells [24,25]. Conversely, when
T-cells are stimulated with interleukin-7 the trafﬁcking of GLUT1 to
the plasma membrane, the uptake of glucose and the subsequent cell
cycle progression are stimulated through a PI3K-Akt dependent
pathway [22,25,26]. An immediate conclusion that stems from the
particular metabolic trait of proliferating cells is that proliferation is
only possible when there is a non-restrained availability of energetic
substrates in the milieu because glycolysis is an energy- and matter-
wasteful pathway (Fig. 1A) [5]. In any case, this “selﬁsh” metabolic
trait provides the cancer cell with the strategy that satisﬁes their
matter and energy demands for tumor growth irrespective of host
considerations (Fig. 1A).
3. Aerobic glycolysis controls progression through the cell cycle
If proliferation is bound to aerobic glycolysis (Fig. 1) the relative
activity of the metabolic pathways relevant for energy provision are
also tightly regulated during the cell cycle of the eukaryotic cell. In
fact, in S. cerevisiae a signiﬁcant number of genes that have functions
in energy metabolism are coordinately and periodically expressed
during the cycle [27,28]. The yeast metabolic cycle can be divided into
three different phases: (i) the oxidative, where the components of the
translational machinery are transcribed and there is peak in RNA
synthesis; (ii) the reductive/building, that comprises the expression
of nuclear genes codifying for mitochondrial components; and (iii)
the reductive/charging, that includes the expression of genes involved
in glycolysis, breakdown of storage of carbohydrates and of the
pentose phosphate pathway [27,28]. Consistently, human lympho-
cytes stimulated to proliferate show a peak in RNA synthesis that is
previous to the triggering of aerobic glycolysis and the onset of DNA
synthesis [21]. Moreover, it has been recently shown that the accretion
of mitochondrial membranes, mitochondrial DNA (mtDNA) and of
several mitochondrial proteins of the respiratory chain is carried out
during the S phase of the cycle [29], temporally coinciding with the
burst of glycolysis (Fig. 1B) that is in the reductive phase of the cycle.
However, fully functional mitochondria are not achieved until the end
of G2/M [29]. At this stage of the cycle a key protein of oxidative
phosphorylation (β-F1-ATPase) is preferentially synthesized by
translational activation of its mRNA [29].
Translation of β-F1-ATPase mRNA in the G2/M phase of the cycle, a
time when cap-dependent translation is arrested [30], is possible
because the 3′ untranslated region (3′UTR) of the mRNA is endowed
with an internal ribosome entry site (IRES)-like activity [31]. Changes in
the translational efﬁciency of thismRNAhave also been reported during
liver development [32] and in cancer cells [33]. These ﬁndings suggest a
relevant role for translation and speciﬁcally of cap-independent
mechanisms of translation, in the control of the appropriate biogenesis
of mitochondria both in normal and in cancer cells [29]. On the other
hand, the full developmentofmitochondria atG2/Mseems to be a likely
mechanism to guarantee that the re-entrance into the oxidative phase of
the cycle happens after the DNA is packaged, the cell cycle is concluded
and the cell is bioenergetically ready to afford the energy demanding
next step of active biosynthesis of the cellular constituents synthesized
in G1 phase.
The supply of energy required to appropriately fulﬁll the tasks of
the oxidative G1 phase of the cycle is stringently controlled before the
cells could enter the reductive S phase. In fact, cells treated with
oligomycin, a speciﬁc inhibitor of themitochondrial H+-ATP synthase,
become reversibly arrested at the G1/S transition [34,35]. Similarly,
Drosophila mutants on a gene that encodes subunit Va of cytochromec oxidase, which limits cellular ATP availability, also arrests cell cycle
progression at the same stage of the cycle [36]. Likewise, cells growing
in a condition of lowglucose availability also fall into cell cycle arrest at
the G1/S boundary [37]. The G1/S arrest is achieved by the so-called
metabolic stress checkpoint that is controlled by the activation of the
AMP-activated protein kinase (AMPK) which triggers the phospho-
rylation of p53 and its subsequent cellular accumulation [37,38].
AMPK is a metabolic sensor of the cellular energy charge that
controls themetabolic activity of the cell by inhibiting ATP-consuming
anabolic processes upon nutrient deprivation [39]. In this regard,
AMPK inactivates HMG-CoA reductase and acetyl-CoA carboxylase,
thus arresting cholesterol and fatty acids biosynthesis, respectively
[40]. Consistently, pharmacologic and/or genetic activation of AMPK
bring about the inhibition of the proliferation of a number of cancer
cells due to G1/S arrest [41]. More recently, it has been shown that
disruption of complex I of the mitochondrial electron transport chain
also speciﬁcally retards cell cycle progression during the G1-S
transition [42]. In this case, the mechanism appears to involve the
production of ROS, another retrograde signaling molecule originated
in mitochondria [42]. In addition, active AMPK repress protein
biosynthesis by the phosphorylation of both TSC2 and raptor, leading
to the suppression of the rapamycin-sensitive mTOR pathway [43,44].
Intriguingly, it has been recently described thatmTOR–raptor complex
may control mitochondrial activity directly and independently of the
previously identiﬁed targets of mTOR (S6K and 4EBPs), suggesting a
reciprocal homeostatic loop of cross-regulation between mitochon-
dria and mTOR activity during cell cycle progression [45,46]. It
appears that cell cycle arrest is an emergency mechanism by which
the cells enter a transient quarantine-like state to avoid energy
depletion that would otherwise induce necrotic and/or apoptotic cell
death. In any case, a sustained energy depletion stress, like a total
glucose withdrawal from the culture media or a restrained blood ﬂow,
would induce apoptosis through the same AMPK-p53 signaling
cascade [47].
Once the cell overcomes the G1/S transition the mitochondrial
bioenergetic activity is repressed as a result of cyclin D1 activity
[48,49]. Cyclin D1 is involved in the phosphorylation and inactivation
of the retinoblastoma protein, a process that marks the entry of cells
into the S phase. Cyclin D1 is expected to control the metabolic switch
from the oxidative to the reductive phase of the cycle to minimize the
production of ROS at a time when the genetic material is most
vulnerable [23,50]. Consistent with this suggestion, it has been shown
that the quenching of ROS produced from dysfunctional mitochondria
bypasses the G1/S checkpoint allowing cellular proliferation [42].
4. Cancer genes and energetic metabolism
Diverse mechanisms have been proposed to explain the metabolic
switch from mitochondrial respiration to glycolysis experienced by
the cancer cell. In particular, those originating from genetic alterations
in oncogenes and/or in tumor suppressors that impact on glycolysis or
in mitochondrial activity and the biogenesis of the organelle.
The oncogene c-myc, which is frequently over-expressed in cancer
cells, is involved in the transactivation of most of the glycolytic
enzymes including lactate dehydrogenase A (LDHA) and the glucose
transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate
to promote the enhanced glucose uptake and lactate release in the
proliferating cancer cell (Fig. 2). More recently, and consistent with
the relevant role of the oncogene in proliferation, c-myc has also been
shown to control the transcriptional expression of essential genes
required for the biogenesis of mitochondria [53] (Fig. 2) and to
functionally coordinate both the metabolic and regulatory events
required for entry and progression through the cell cycle [54]. In this
regard, it has been reported that the c-myc dosage is important for
sustaining tumorigenesis [55] because the expression of its targeted
genes depends on c-myc expression levels [56].
Fig. 2. Cancer genes and energetic metabolism. The diagram shows several pathways that could promote the glycolytic phenotype of cancer cells. Proliferation favors the glycolytic
production of ATP and restrains the bioenergetic activity of mitochondria. Gain-of-function mutations in the oncogenes Akt and c-myc lead to an increased glycolysis through
induction of the glucose transporter GLUT1 and/or of glycolytic enzymes. Loss-of-function mutations in the tumor suppressor p53 cause the simultaneous induction of glycolysis and
an impairment of mitochondrial respiration, thus promoting aerobic glycolysis. The hypoxic environment of tumor cells induces the stabilization of HIF1α, which enforces glycolysis
by promoting the concurrent expression of glycolytic enzymes and restraining oxidative phosphorylation. In addition, mtDNA and nDNA mutations that limit mitochondrial activity
could favor the glycolytic pathway in cancer cells. Deﬁciencies in mitochondrial metabolic and respiratory functions could cause both an increase in ROS and of the metabolic
intermediates succinate and fumarate, which in turn could provoke the stabilization of HIF1α leading to a positive feed-forward cycle of glycolytic enforcement. Loss-of-function
mutations of VHL cause a failed degradation of HIF1α that could inhibit mitochondrial biogenesis by activation of the c-myc inhibitor MXI1. For other details, see the text.
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hypoxic microenvironment. Hypoxia results in the stabilization of the
transcription factor hypoxia inducible factor 1 alpha (HIF1α), which in
turn induces the expression of GLUT1 and of many glycolytic enzymes
as well as of the factors that trigger angiogenesis (VEGF) and cell
growth and survival pathways (IGF-2) [57,58]. Recently, it has been
reported that c-myc and HIF1α cooperate to induce the expression of
pyruvate dehydrogenase kinase 1 (PDK1) and hexokinase II (HK-II)
targeting in this way the two pathways of energetic metabolism and
favoring the glycolytic phenotype of the cancer cell [59]. Indeed, the
expression of PDK1, a protein that phosphorylates and inactivates the
pyruvate dehydrogenase complex (PDH), inhibits the mitochondrial
metabolism of pyruvate (Fig. 2) [53,60,61]. On the other hand, HIF1α
also alters the activity of cytochrome c oxidase (COX) by changing the
molecular composition of complex IV of the respiratory chain (Fig. 2). It
seems that the preferred expression of COX4-2 in hypoxia (instead of
COX4-1) contributes to a more efﬁcient transfer of electrons to O2
therefore limiting the amountof ROSgenerated in this situation [62]. In
addition, it has been shown that a gain of function ofHIF1α in renal cell
carcinomas indirectly represses the biogenesis of mitochondria [63].
This situation originates from a deﬁcient von Hippel-Lindau (VHL)
factor that renders a constitutive activation of HIF1α under normoxic
conditions (Fig. 2) [64–66]. HIF1α also induces the expression ofMXI1,which inactivates c-myc and in turn could decrease the c-myc
promoted mitochondrial biogenesis (Fig. 2) [63,67].
The oncogene Akt is a critical molecule in the transduction of
signals that convey proliferation and apoptotic resistance [68]. An
enhanced glycolytic metabolism seems to be essential for Akt-
mediated cell survival upon growth factor withdrawal [69]. In
addition, Akt promotes a dose-dependent stimulation of glycolysis
(Fig. 2) that correlates with tumor aggressiveness in vivo [70]. In this
regard, over-expression of Akt in non-invasive radial-growth mela-
nomas induces the expression of glycolytic markers, stimulates
glycolysis as well as transformation of the tumor to an invasive
vertical-growth phenotype [71]. Recently, mitochondrial respiratory
defects caused by genetic manipulation, chemical or hypoxic stresses
have been shown to promote the inactivation of PTEN through a redox
mechanism leading to Akt activation (Fig. 2) that results in drug
resistance and survival advantage in hypoxia [72]. Furthermore, the
PTEN/Akt/mTOR pathway also activates HIF1α (Fig. 2) thus reinfor-
cing the shift frommitochondrial to glycolytic production of energy in
cancer cells [73].
The tumor suppressor protein p53 also promotes the glycolytic
phenotype of cancer cells. On the one hand, over-expression of a
dominant negative mutant p53, a situation that is found in many
tumors, leads to the induction of HK-II and to an increased glucose
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(TP53-induced glycolysis and apoptotic regulator), an inhibitor of
fructose bisphosphatase-2, and down-regulates the expression of the
glucose transporter GLUT1 [76,77]. Consequently, loss-of-function of
p53 results in the down-regulation of TIGAR and the up-regulation of
GLUT1, which in turn results in an enhancement of glycolysis (Fig. 2)
[76–78]. On the other hand, it has been reported that p53 can regulate
the activity of mitochondrial respiration through the activation of
SCO2, which is a critical factor for assembling the cytochrome c
oxidase (COX) complex (Fig. 2) [79]. Loss-of-function of either p53 or
SCO2 results in a decreased rate of mitochondrial respiration and a
metabolic shift toward glycolysis [79].
In addition to the metabolic trait imposed by proliferation and the
effects of the hypoxic environment where the tumor develops it is also
possible that the enforced aerobic glycolysis of tumors could result
frommutations in nuclear and/or mitochondrial genes that impact on
mitochondrial activity (Fig. 2). In this regard, it has been found that
mutations in succinate dehydrogenase and fumarate hydratase
predispose to different neoplasia syndromes (for review see [80]).
Moreover, it has been reported that the accumulation of the Krebs
cycle intermediates succinate and fumarate triggers the stabilization
of HIF1α by inhibiting the prolyl-hydroxylase involved in the
degradation of the transcription factor (Fig. 2) [81,82]. Consistent
with the idea of retrograde signaling bymitochondria [83], it has been
suggested that other metabolites such as pyruvate, oxaloacetate as
well as ROS may stabilize HIF1α and thus provide in normoxic cells a
positive feedback cycle of regulation [84,85].
Multiple mtDNA mutations that interfere with oxidative phos-
phorylation, increase ROS production and promote tumor cell
proliferation have been described in tumors (Fig. 2) [86]. For instance,
complexes of themitochondrial respiratory chain exhibit a diminished
activity in cancer due to a decreased expression of the subunits
encoded by mitochondrial DNA [87]. Cells totally depleted of mtDNA
(ρ0 cells) have been used to asses the inﬂuence of mtDNA in tumor
progression. However, these studies have yielded conﬂicting
results [88,89]. It has been argued that ρ0 cells are not good represen-
tatives of tumor cells because cancer cells are not completely de-
pleted of mtDNA. Therefore, studies with mtDNA-partially depleted
cells (ρ- cells) or cells with deﬁned mtDNA point mutations are
nowadays being characterized to assess the contribution of mtDNA in
cancer progression. The cybrid technology [90] developed in the
laboratory of the late mitochondriologist Giuseppe Attardi (Pasadena,
CA, 2008) has been especially useful in this regard. Using this model
system different mtDNA mutations and partial mtDNA depletions
have been related to tumorigenicity [91], tumor growth [92],
metastasis [93] and invasion [94].
5. Translation of mitochondria into the clinics: a protein signature
of energetic metabolism
In hepatomas, the complement of mitochondria is down-regulated
when compared to paired normal hepatocytes [33,95]. Moreover,
mitochondria in hepatomas have less cristae than in the normal cell
[13], further supporting that the mitochondrial bioenergetic activity is
compromised in cancer. Fetal rat hepatocytes very much resemble the
mitochondrial phenotype of hepatomas, from the point of view of both
the complement and activity of mitochondria ([96], for review see
[97]) as well as of the mechanisms that regulate the expression of the
catalytic β-F1-ATPase subunit of the mitochondrial H+-ATP synthase
([32,98], for review see [6]). The metabolic and enzymatic analogies
that exist between the phenotype of cancer cells and embryonic tissues
have already been summarized [6]. However, it is worth mentioning
here that the rapid changes that occur in the bioenergetic phenotype of
liver mitochondria at the time of birth [96,98] mechanistically
resemble very closely those that occur during cellular transformation
[32,33]. Moreover, it has been documented that the expression ofmarkers of mitochondrial energy metabolism during development of
the liver inversely correlate with the expression of markers of the
glycolytic pathway [6]. These observations prompted us to design a
simple assay of the protein signature of energy metabolism [13] that
could be translated into the cancer ﬁeld with the purpose of
contrasting the feasibility of the Warburg hypothesis [7,8].
With this aim, we studied in normal and tumor biopsies derived
from the same patients the expression level of two mitochondrial
proteins: β-F1-ATPase and Hsp60, respectively representing a bio-
energetic and a structural mitochondrial protein. We completed the
study by determining the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), used here as a representative of the
glycolytic pathway [13,99]. This approach allows a protein estimation
of both the bioenergetic competence of the organelle (assessed by the
β-F1-ATPase/Hsp60 ratio) and of the overall mitochondrial potential
of the cell (β-F1-ATPase/Hsp60/GAPDH ratio), the two levels that
could reveal a compromised bioenergetic activity of mitochondria in
the cancer cell [13]. This point is very relevant because, depending on
the type of neoplasia being considered, a reduction of total
mitochondrial mass or a speciﬁc reduction of the expression of
β-F1-ATPase is observed in the tumors [13]. The ratio that estimated
the overall mitochondrial potential of the cell was deﬁned as the
BioEnergetic Cellular (BEC) Index [13] which has been recently
simpliﬁed to the β-F1-ATPase/GAPDH ratio [14].
Fig. 3A shows a representative example of these determinations by
western blotting in surgical specimens of colon cancer patients. It is of
interest noting the variability that could be observed for the
expression of β-F1-ATPase between the tumors of the two patients
depicted in the almost complete absence of changes for the expression
of Hsp60 (Fig. 3A). As a result of these changes, colon cancers show a
signiﬁcant reduction of the β-F1-ATPase/Hsp60 ratio when compared
to paired normal colon tissue (Fig. 3A), suggesting a deﬁcit in the
bioenergetic competence of the mitochondrion [13]. Remarkably, and
consistent with Warburg's postulates, these changes in the mitochon-
drial proteome of the tumor were accompanied by the concurrent
sharp increase of the glycolytic GAPDH marker (Fig. 3A). Consistently,
the estimation of the overall mitochondrial activity of the cell relative
to its glycolytic potential (BEC index), revealed larger differences
between normal and tumor tissue (Fig. 3A), supporting a bioenergetic
deﬁcit of mitochondria in colon cancer [13]. This analysis, that was
deﬁned as the bioenergetic signature of cancer [13], was extended to
most prevalent human tumors [99]. The results obtained revealed that
the down-regulation of the β-F1-ATPase protein provides a proteomic
feature of many different types of human carcinomas [13,14,99–101]
with the exception of prostate cancer [99]. These ﬁndings have been
largely conﬁrmed in other laboratories ([102] and see [5] for extensive
review).
The reported changes in the bioenergetic signature of colon, lung,
breast, gastric, esophageal and renal cancer suggested, at the protein
level, a bioenergetic impediment of mitochondria of the cancer cell in
these tissues. Functional demonstration of this point came when the
expression level of β-F1-ATPase and the bioenergetic signature of lung
cancer were shown to correlate inversely with the rate of glucose
capture of the tumors as assessed in vivo by FDG-PET imaging and
with the rates of aerobic glycolysis of cancer cells [14], strongly
supporting that the down-regulation of the bioenergetic function of
mitochondria is a hallmark of cancer and part of the mechanism that
triggers the increased glucose avidity of the cancer cell. Therefore, the
bioenergetic signature also informs of the functional activity of energy
provision pathways.
The transfer of results obtained at the bench-side in beneﬁt of the
management and treatment of patients is often hampered by the lack
of clinically oriented studies and by the availability of the adequate
tools required to implement such ﬁndings in the patient's setting. A
paradigm of this desperately common and frustrating situation is the
discovery of many cancer biomarkers and its rare translational
Fig. 3. The bioenergetic signature of colon cancer. (A) Expression of β-F1-ATPase, Hsp60 and GAPDH in normal (N) and tumor (T) biopsies of two different colorectal cancer patients
(X, Y). Histograms to the right illustrate the drop in β-F1-ATPase/Hsp60 ratio and the concurrent increase in the expression of the glycolytic GAPDH in colon cancer. Consistent with
these changes, the BEC index of the tumors is sharply diminished when compared to paired normal colon. For other details see the text. These data has been taken and redrawn from
reference [13]. ⁎, illustrates signiﬁcant differences when compared to normal. (B) Immunohistochemical analysis of the expression of β-F1-ATPase, Hsp60 and GAPDH in colorectal
carcinomas using colon-tissue microarrays. Histograms to the right illustrate the absolute amount (a.u.) of the expression of β-F1-ATPase and GAPDH (O. D.) and of the BEC index in
normal (N) and tumor (T) samples derived from patients with progressive disease (blue bars) and no-evidence of disease (red bars) after a median of 60 months clinical follow up.
These data has been taken and redrawn from reference [13]. ⁎ and #, illustrate signiﬁcant differences when compared to normal or no-evidence of disease group, respectively. (C)
Kapplan–Meier disease-free survival (DFS) analysis of colon cancer patients [13] reveals the signiﬁcant association of the expression level of β-F1-ATPase with metastatic disease.
High and low expression levels of β-F1-ATPase for red and blue curves, respectively. Log-rank signiﬁcance is indicated. Cox regression analysis revealed a signiﬁcant higher relative
risk of disease recurrence in patients expressing low levels of β-F1-ATPase.
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signature of tumors in large cohorts of different cancer patients
[13,14,100,101]. Figs. 3B and C provide a representative example of thissort of study with a cohort of stage II colon cancer patients [13]. In this
case, the expression of markers of the bioenergetic signature was
carried out by immunohistochemistry using colon-tissue microarrays
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other approaches in a reduced cohort of the same type of cancer
patients (Fig. 3A) [13]. Indeed, it was observed that the expression of
β-F1-ATPase and the BEC index were signiﬁcantly reduced in colon
cancer when compared to paired normal tissue (Fig. 3B). However, it
was outstanding that the expression of β-F1-ATPase in tumors of the
patients that had recurrence of the disease was much less than that in
tumors of patients that survive colon cancer (Fig. 3B) [13]. Consistent
with this observation, it was found that tumor β-F1-ATPase expression
afforded an excellent marker of both the overall and disease-free
survival (Fig. 3C) of colon cancer patients [13]. In fact, the tumor
expression of β-F1-ATPase allows the discrimination of the patients
that have a higher risk of disease recurrence (Fig. 3C). Similarly, the
bioenergetic signature has also been shown to provide relevant
markers of disease progression in lung [14,100] and breast [101] cancer
patients, strongly supporting the relevant role that the mitochondrial
impairment of the cancer cell plays in progression of the disease. Very
recently, our ﬁndings on the clinical utility of β-F1-ATPase as marker of
colon cancer prognosis have been conﬁrmed in a different large cohort
of colon cancer patients [102]. Interestingly, in that study it is shown
that neither mtDNA content nor the tumor expression of TFAM
provided markers of prognosis in colon cancer [102].
The speciﬁc molecular mechanisms that promote the down-
regulation of the mitochondrial β-F1-ATPase in the cancer cell remain
to be determined. However, as indicated previously, the expression of
β-F1-ATPase during development of the liver [32,98,103,104], pro-
gression through the cell cycle [29] and in liver carcinogenesis [6,33] is
regulated by post-transcriptional mechanisms that affect the sub-
cellular localization, the stability and the translation of the mRNA. The
3′UTR of β-F1-ATPase mRNA is essential for efﬁcient translation of the
transcript [31,32,105]. It appears that translationmasking of themRNA
is due to the binding of proteins (β-mRNABPs) to the 3′UTR of the
transcript which presumably hamper its role in translation [6,32,33].
Within this context, we have pursued the identiﬁcation of the β-
mRNABPs that interact and could deﬁne the bioenergetic phenotype
of the cancer cell in order to establish its relevance as markers of
breast cancer progression.
The AU-rich element (ARE) binding protein HuR, a central
regulator of post-transcriptional gene expression [106] whose activity
and sub-cellular localization is tightly regulated during the cell cycle
[107,108] and that controls the expression of cell cycle relevant
proteins [107–109], has been identiﬁed as a 3′UTR β-mRNA interac-
ting protein [110]. Mechanistically, HuR over-expression and shRNA-
mediated silencing in different human cells indicate that the protein is
not regulating β-F1-ATPase expression [110]. However, the analysis of
the expression of HuR in a large cohort of breast carcinomas has
pointed out its relevance as an independent marker of breast cancer
prognosis [110]. In fact, when HuR expression is studied in combina-
tion with the bioenergetic signature of the tumor it allows the
identiﬁcation of breast cancer patients at higher risk of disease
recurrence [110]. These results strongly encourage the incorporation
of HuR as an additional protein marker of the bioenergetic signature
for the follow-up of breast cancer patients.
Mitochondrial activity and speciﬁcally oxidative phosphorylation
play a relevant role in facilitating the execution of cell death (see
Section 6 The tumor suppressor function of mitochondrial activity)
[34]. In this regard, it appears that the bioenergetic signature of the
cell or tumor also affords a marker of the cellular response to
chemotherapy in colon [111] and liver [34] cancer cells. Recently, the
down regulation of β-F1-ATPase expression in colon cancer patients
has been shown to provide a signiﬁcant predictive marker of the
response of the tumors to the treatment with 5-ﬂuorouracil [102].
Overall, the relevance of protein markers of energetic metabolism in
the prognosis and eventual treatment of cancer patients provide
strong support to push forward the translation of mitochondria into
the cancer ﬁeld. The development of high afﬁnity and speciﬁcmonoclonal antibodies against these markers, as well as the
methodology to quantify its expression in tumor biopsies (Acebo et
al., unpublished data), has represented an additional step forward of
our lab in bridging mitochondrial research to the bedside of cancer
patients.
6. The tumor suppressor function of mitochondrial activity
Deregulated cell division and cell death are hallmarks of cancer
acquired by defects in signaling pathways [2]. Mitochondria play an
essential role in cell death [112,113]. Different stimuli that converge at
the mitochondrial level provoke the permeabilization of its outer
membrane and the subsequent release of different proteins that
participate in the execution of cell death [114]. Mitochondrial geared
cell death is regulated by members of the Bcl-2 family of proteins
[115–117]. To evade apoptosis cancer cells develop different strategies
such as the inactivation of p53 [118,119], induction of senescence
[120], disruption of the Fas–death receptor pathway [121], upregula-
tion of inhibitors of apoptosis (IAPS) [122], down-regulation of
caspases [123,124], the activation of the PI3K/Akt/PTEN pathway
[125] and the restriction of the bioenergetic activity of mitochondria
[34,113]. Indeed, the generation of ROS that mostly depends on the
activity of mitochondrial respiration is known to promote changes in
the signal transduction pathways that control the expression of genes
required to execute cell death [126,127].
Cellular metabolism is molecularly and functionally integrated
with cell death [128–131] and both oxidative phosphorylation and the
H+-ATP synthase itself [34,132–136] are required for the efﬁcient
execution of death. In this regard, Bax induced toxicity in yeast cells
has been shown to require oxidative phosphorylation [137]. Screens
aimed at the identiﬁcation of genes that could confer a Bax-resistance
phenotype have identiﬁed a subunit of the H+-ATP synthase critical
for Bax-mediating killing of S. cerevisiae [134]. Moreover, Bax-
mediated killing has been shown to be strictly dependent upon the
nuclear encoded β-subunit of the H+-ATP synthase (β-F1-ATPase)
and mitochondrial genome-encoded proteins [138]. Recent studies in
mammalian cells have further provided an insight on the mechanism
of participation of the H+-ATP synthase in the execution of cell death
[34]. It has been shown that this complex is involved in the generation
of ROS in the early induction phase of programmed cell death [34].
ROS are further responsible for the oxidation and covalent modiﬁca-
tion of mitochondrial constituents [34] facilitating in this way the
release of the mitochondrial proteins [34] that effectively swamp the
cells into death. Indeed, inhibition of ROS production with oligomycin
prevented thesemodiﬁcations [34], strongly supporting the role of the
H+-ATP synthase in controlling the extent of mitochondrial damage
and the execution of cell death.
Moreover, it appears that the dependence on oxidative phosphor-
ylation for cellular ATP provision deﬁnes the susceptibility of a cell to
execute ROS-dependent cell death by the mitochondrial geared
pathway [34], in agreement with other reports [132,133,135,137] and
with the role of the H+-ATP synthase in cell death [134,138]. In line
with these ﬁndings, we have recently veriﬁed that cells that rely
heavily on glycolysis for energy provision display an apoptotic resistant
phenotype [34] similar to ρ° cells [132,133,135] because ROS signaling
after chemotherapeutic targeting of the mitochondria is blunted [34].
Therefore, it is not surprising that the expression of the H+-ATP
synthase, and perhaps of other OXPHOS complexes, is down-regulated
in most human tumors (for review see [5]).
Themetabolism of cancer cells is relevant for cancer treatment and
could deﬁne the pathway and response of the tumor to chemotherapy
and/or radiotherapy (Fig. 4). In cancer cells with an active oxidative
phosphorylation ROS production after therapy can engage cells into
any of the pathways of programmed cell death (Fig. 4) [113]. In
contrast, cancer cells with a predominant aerobic glycolysis will
become resistant to the same therapy (Fig. 4). Therefore, the strategy
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rylation may restore the cell sensitivity to apoptotic inducers and
promote arrest of tumor growth. Alternatively, the strategy in
glycolytic tumors might be the employment of alkylating agents
that kill cells by programmed necrosis (Fig. 4) [139].
The renaissance of energetic metabolism of cancer cells has
encouraged investigations aimed at establishing a link between this
metabolic trait and tumor growth. Different experimental approaches,
from cell lines to animal models aside from those already discussed,
have been used to address this issue and are summarized in the
following. Frataxin, a mitochondrial protein defective in Friedreich
ataxia, is known to increase oxidative metabolism and ATP synthesis
[140] probably by interactingwith respiratory chain components [141]
and/or by regulating the synthesis of Fe/S clusters [142]. Patients
suffering from Friedreich ataxia, (i.e., with low frataxin levels) have a
defective ATP synthesis and occasionally develop tumors at an
unusual young age. Recently, a model of down-regulation of mito-
chondrial function was created by disrupting the frataxin gene in the
liver of mice [142]. Consistent with Warburg's postulates, the frataxin
knockout mice had a shortened life span and the mitochondrial
impairment displayed in the hepatocytes was accompanied by tumor
development [142]. Conversely, the same group has shown that theFig. 4. Energetic metabolism and cell death. Cancer cells have different susceptibility to
death induced by chemotherapeutic drugs as a result of their metabolic phenotype. A
ﬁrst event after priming the cell to death is the rapid dismantling and fragmentation of
the mitochondrial tubular network into small mitochondria (in green). Tumor cells
relying on oxidative phosphorylation (OXPHOS) for energy provision showa rapid burst
in ROS production that oxidizes mitochondrial proteins (red dots) favoring in this way
the release of mitochondrial proteins that will effectively swamp the cell into
programmed cell death (fragmented nucleus in blue). Cancer cells that have a high
glycolytic metabolism have a diminished and/or blunted ROS response to chemother-
apy and experience no relevant cell death. In this situation it is suggested that metabolic
inhibitors targeting energetic metabolism could kill the cancer cell by programmed
necrosis (blast of cell in light blue).over-expression of frataxin in colon cancer cells triggers an increase in
oxidative metabolism concurrent with a decrease in cellular growth
rates, colony forming capacity as well as the tumorigenicity of the cells
when injected into nude mice [143]. Taken together, the frataxin
models support that interfering with mitochondrial function predis-
poses to cancer development and tumor growth.
Another experimental system linking defective oxidative phos-
phorylation and tumor growth is provided by studies with the von
Hippel-Lindau (VHL) tumor suppressor. When VHL deﬁcient cells
ectopically expressing a functional pVHL protein are injected into nude
mice, tumor formation and growth is retarded [144]. At that time VHL
was described as a key player in the regulation of tumor glycolysis due
to its ability to bind and promote the oxygen dependent degradation of
HIF1α (Fig. 2) [145]. In recent years, VHL has also been described as an
activator of oxidative phosphorylation because VHL deﬁcient cells
ectopically expressing wild-type pVHL triggered the biogenesis of
mitochondria and a concurrent increase in the functional activity of
oxidative phosphorylation [146]. Therefore, it seems reasonable to
conclude that VHL deﬁciency is one of the factors responsible for the
down-regulation of the biogenesis of mitochondria while promoting
the activation of glycolysis via HIF1α in some tumors (Fig. 2).
Genetic and metabolic stresses of mitochondria have been used to
assess that a dysfunctional oxidative phosphorylation is also associated
with the trait of invasion andmetastasis of the cancer phenotype. In this
regard, it has been shown that the non-invasive tumor A549 cells
become highly invasive when subjected to the above mentioned
manipulations [147,148]. Likewise, a genetic stress in mitochondria of
C2C12 cells also results in an invasive phenotype of the manipulated
cells [148]. The mechanism appears to involve the over-expression of
cathepsin L (an extracellular matrix protease) and TGFβ, which are
relevant markers of invasive tumors [148]. These results have been
further conﬁrmed in osteosarcoma cells, in which defects in oxidative
phosphorylation induced by similar approaches (mtDNAdepletion and/
or mutations, exposure to KCN and hypoxia) promote cellular invasive-
ness as well as changes in the expression of genes involved in the
remodeling of the extracellular matrix [94]. Overall, these ﬁndings
support that the activity of mitochondrial oxidative phosphorylation
might also play a role in cell migration and tissue invasion.
The mitochondrial PDH complex is a key enzyme that regulates the
ﬂux between glycolysis and oxidative phosphorylation due to its
positioning at the cross-road of both metabolic pathways [5]. The
activity of the complex is inhibited by pyruvate dehydrogenase kinases
(PDKs) that phosphorylate the pyruvate dehydrogenase E1α subunit of
the complex. Inhibition of PDK1 expression in human carcinoma cells
diverts pyruvate to mitochondrial metabolism promoting the activity of
oxidative phosphorylation [85]. The activation of PDH also has an effect
in preventing cell proliferation and invasion. The knockdown of PDK1 in
metastatic cells reveals that they are more prone to die in hypoxic
conditions, release less VEGF and form tumors with a reduced growth
rate [85], highlighting the beneﬁcial effect that restoring mitochondrial
metabolism have in tumor progression.
Finally, glycolysis interfering models have also been developed to
study the link between aerobic glycolysis and tumor growth. In this
regard, it has been shown that knocking down the glycolytic enzyme
LDHA in mouse mammary tumor cells trigger a reduction in the
tumorigenicity and tumor growth rate of these cells when trans-
planted into mice [149]. Moreover, LDHA knockdown cells exhibited
increased mitochondrial function and compromised ability to pro-
liferate under hypoxia [149]. These results show the tight connection
that exists between glycolysis and oxidative phosphorylation in this
speciﬁc case mediated by the cytoplasmic enzyme placed at the
branch point of pyruvate metabolism [5]. These ﬁndings also conﬁrm
that inhibition of glycolysis can restrict the ability to proliferate of
cancer cells. Overall, all these ﬁndings with different cellular and
animal models strongly support and conﬁrm Warburg's postulates,
i.e., the bioenergetic activity of mitochondria of the cancer cell must
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putable tumor suppressor function.
7. Energetic metabolism provides a promising target for
cancer treatment
Nowadays, it is accepted that the peculiarmetabolism of the cancer
cell provides a target to develop strategies that could halt disease
progression [4,12]. In this regard, several small molecules interfering
with cancer speciﬁc metabolic pathways are being tested either alone
or in combined chemotherapy. Table 1 summarizes some of the
compounds that are currently being evaluated for clinical use in the
treatment of cancer and are discussed in the following.
The non-metabolizable glucose analogue 2-deoxyglucose (2-DG)
blocks glycolysis [150,151] because 2-DG is phosphorylated by hexoki-
nase and cannot be further metabolized, leading to the exhaustion of
cellular ATP and cell death [152]. 2-DG treatment sensitizes gliomas to
radiation therapy [153] and increases the efﬁcacy of several che-
motherapies in osteosarcomas, head and neck, and colon cancer cells
[154–156]. Like 2-DG, 3-bromopyruvate (3-BrPA) has been shown to
abolish the production of ATP by inhibiting the glycolytic enzyme
hexokinase [157–159]. Hexokinase II, that is over-expressed in carcino-
mas [160–162] bound to themitochondria [163], has a central role in the
regulation of cell death [164]. The efﬁcacy of the small alkylating agent
3-BrPA in the eradication of liver-implanted tumors and in the induction
of apoptosis has been successfully tested in vivo without apparent
toxicity [157,158,165]. Recent studies using FDG-PET have evaluated the
antitumor activity and biodistribution of 3-BrPA in a rabbit tumormodel
[166,167].
Several other small compounds have also been tested as
chemotherapeutic agents. In fact, the anticancer activity of iodoacetic
acid (IAA), a well known inhibitor of glycolysis that targets GAPDH
[168], has shown anti-tumor activity in an ascites tumor model [169].
Lonidamine, represses glycolysis by inactivation of hexokinase [170]
and enhances the radiation effects on mice tumor models [171]. The
ability of lonidamine to suppress the energy metabolism of cancer
cells and to improve the activity of other anticancer agents has led to
phase II–III clinical trials of this compound in combination with other
anticancer agents for the treatment of glioblastomas, breast, ovarian,
and lung cancers [172–175]. The glycolytic inhibitor, 5-thioglucoseTable 1
Small compounds targeting themetabolism of the cancer cellwith potential clinical utility.
# Compound Metabolic process Target Clinical trials
1 2-deoxyglucose Glycolysis Hexokinase Phase I/II
2 3-bromopyruvate Glycolysis Hexokinase Pre-clinical
3 Lonidamine Glycolysis Hexokinase Phase II/III
4 5-thioglucose Glycolysis Hexokinase Pre-clinical
5 Mannoheptulose Glycolysis Glucokinase Pre-clinical
6 Iodoacetic acid Glycolysis GAPDH Pre-clinical
7 α-chlorohydrin Glycolysis GAPDH –
8 Ornidazole Glycolysis GAPDH –
9 Oxalate Glycolysis PK Pre-clinical
10 Somatostatin Glycolysis PK Phase I–III
11 Dichloroacetate Pyruvate oxidation PDK1 Phase I/II
12 Glufosfamide Glycolysis/PPP Glucose transporter Phase I/II
13 6-aminonicotinamide PPP G6PD Pre-clinical
14 Oxythiamine PPP TK Pre-clinical
15 Arsenite apoptosis MOMP Pre-clinical
16 Betulinic acid apoptosis MOMP Phase I/II
17 Jasmonates apoptosis MOMP Pre-clinical
18 Soraphen A Fatty acid synthesis ACC Pre-clinical
19 Cerulenin Fatty acid synthesis FAS Pre-clinical
20 Etomoxir β-oxidation CPT1 Pre-clinical
GAPDH, glyceraldehyde 3-P-dehydrogenase; PK, pyruvate kinase; PDK1, pyruvate
dehydrogenase kinase 1; G6PD, glucose-6-phosphate dehydrogenase; TK, transketo-
lase; MOMP, mitochondrial outer membrane permeabilization; ACC, acetyl-CoA
carboxylase; FAS, fatty acid synthase; CPT1, carnitine palmitoyl transferase 1; PPP,
pentose phosphate pathway.(5-TH), has also been classiﬁed as an antineoplastic agent because it
promotes a drop in glucose uptake and under hypoxic conditions
triggers the induction of cell death [176–178]. Somatostatin and its
structural analogue, TT-232, have been found to interact with type M2
of pyruvate kinase (PKM2). PKM2 is over-expressed during oncoge-
nesis and presumably responsible for diverting glycolytic pyruvate
away from mitochondria [179]. It appears that the translocation of
PKM2 to the nucleus in response to TT-232 treatment is sufﬁcient to
induce cell death [180].Mannoheptulose is another non-metabolizable
glucose analog with known anticancer effects that inhibits glucoki-
nase activity, decreases glucose uptake and suppresses tumor cell
growth in an ascites tumor model [181,182]. Glufosfamide, a new
alkylating agent that uses the transport system of glucose [183],
has been successfully tested in pancreatic and other cancer cells
[184–186]. Glufosfamide treatment also enhances the reduction of
pancreatic tumors when used in combinationwith gemcitabine [187].
There are several other compounds that inhibit glycolytic metabolism
although their effects as anticancer agents remain to be studied. Of
note, α-chlorohydrin and ornidazole, that inhibit GAPDH [188,189] and
oxalate, that inhibits pyruvate kinase (PK) [190].
Another plausible approach to exploit the energetic metabolism
with anticancer purposes is the enhancement of mitochondrial
activity [85,143,149]. In this regard, dichloroacetate (DCA), a small
molecule used in the past to treat metabolic disorders [191] has
proven its utility in promoting apoptosis and halting tumor progres-
sion in mice models without apparent toxicity [192]. DCA is a well-
characterized inhibitor of PDKs [193] that shifts the metabolism of
pyruvate from glycolysis to its terminal oxidation. A recent study has
also demonstrated that DCA is effective in sensitizing invasive
endometrial cancer cells to apoptosis [194].
Molecules promoting the pro-apoptotic activity of mitochondria
that trigger outer membrane permeabilization (MOMP) have also
been proposed as anticancer agents (for review see [195]). In this
regard, Arsenite has been shown to sensitize human melanomas to
apoptosis via tumor necrosis factor-alpha (TNF-α)-mediated pathway
[196,197]. Betulinic acid, a natural pentacyclic triterpenoid, has proven
its ability to induce apoptosis in tumor cells via the mitochondrial
pathway and also to stimulate the effect of several anticancer drugs
[198,199]. Jasmonates, which are plant stress hormones, induce cyto-
chrome c release and mitochondrial swelling in cancer cells but not in
their normal cells counterparts [200,201].
The pentose phosphate pathway (PPP) rate-limits cell proliferating
because it provides the ribose required for nucleic acid biosynthesis
[5]. It has been suggested that the inhibition of transketolase (TK)
would cause deprivation of glyceraldehyde-3-phosphate and hence
limit ATP generation, as well as the NADPH and ribose required for
macromolecule biosynthesis [202,203]. Indeed, oxythiamine, an irre-
versible inhibitor of TK, decreases tumor growth both in vitro and in
vivo [202,203]. The PPP can also be interfere by 6-aminonicotinamide
(6-AN) that inhibits the activity of glucose-6-phosphate dehydrogen-
ase (G6PD). The anticancer activity of 6-AN is mediated through
oxidative stress and in combined therapy contributes to sensitize the
cells to radiation and other anticancer agents [204–206].
Cancer progression requires the biosynthesis of essential lipid
components of biological membranes. The fatty acid synthase (FAS), a
multifunctional enzyme, is over-expressed in most human cancers
[207–211] and the inhibition of FAS activity by cerulenin promotes
apoptosis in several cancer cell lines [208,212,213]. Moreover,
soraphen A, an inhibitor of acetyl-CoA carboxylase (ACC), has been
shown to induce growth arrest in cancer cells [214]. Etomoxir, the
speciﬁc inhibitor of carnitine palmitoyl transferase 1 (CPT1), which is
a bottleneck for the entrance and oxidation of fatty acids in the mito-
chondria, might as well have some beneﬁcial effects in the treatment
of cancer [154]. Therefore, it appears that the peculiar lipid
metabolism of cancer cells also affords an attractive target for cancer
therapy.
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The genetic and epigenetic changes that trigger cellular transfor-
mation are invariably bound to an increase in the glycolytic ﬂux and a
restrain in the bioenergetic function of mitochondria. This is so,
because cellular proliferation is controlled by the synchronous
changes in the activity of the two energy provision pathways as the
cells progress through the different phases of the cycle. The
“metabolic cycle” is expressed in tumors at the proteome level by
signiﬁcant reductions in the relative expression of β-F1-ATPase when
compared to paired normal tissue. The “abnormal” expression of this
relevant marker of mitochondrial energy transduction further
provides a bioenergetic signature of the tumor with potential clinical
utility for the prognosis and eventual treatment of cancer patients.
Moreover, the metabolic hallmark of cancer further affords a target for
the development of new anti-tumor therapies. It is obvious that
during the last decade we have experienced a boost in the interest of
mitochondria because of its relevance in programmed cell death and
in a growing number of human diseases. However, our knowledge of
the mitochondria in the different human tissues that could develop a
neoplasia is negligible; mostly, because the molecular composition,
the number and functional relevance of the organelle is very different
from one tissue to another. Therefore, we urgently need to study the
speciﬁc mechanisms that control the biogenesis of mitochondria in
the different mammalian tissues in order to understand the real
contribution of mitochondria to the different types of cancers. Overall,
there is much to be done ahead in this ﬁeld and the laboratories
traditionally involved in mitochondrial research are excellently suited
and socially compelled to embark in the struggle against cancer and to
promote the basic and clinical advances required to deﬁnitively
transform cancer into a chronic disease.
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